For pharmaceutical and biologics companies, the inability to predict, visualize, and confirm infusate coverage of target regions can be a major hurdle in clinical development—and a potential cause for therapeutic inefficacy. Without intraoperative monitoring, it may be challenging to determine how differences in surgical approaches, cannula designs, vector volumes, and dosing affect coverage within the brain (1).
Join leading gene therapy clinical trialist, Dr. Paul Larson, Professor of Neurosurgery at the University of Arizona and Chief of Neurosurgery at the Southern Arizona VA, to hear his insights on the potential impact of MRI-guided intra-parenchymal delivery of gene therapy in clinical trials. A live Q&A session will follow.
(1) Richardson RM, et al. Data-driven evolution of neurosurgical gene therapy delivery in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2020;91(11):1210-1218.